The outbreak of the new coronavirus infections COVID-19 in December 2019 in China has quickly become a global health emergency. Given the lack of specific anti-viral therapies, the current management of severe acute respiratory syndrome coronaviruses (SARS-CoV-2) is mainly supportive, even though several compounds are now under investigation for the treatment of this life-threatening disease. COVID-19 pandemic is certainly conditioning the treatment strategy of a complex disorder as rheumatoid arthritis (RA), whose infectious risk is increased compared to the general population because of an overall impairment of immune system typical of autoimmune diseases combined with the iatrogenic effect generated by corticosteroids and immunosuppressive drugs. However, the increasing knowledge about the pathophysiology of SARS-CoV-2 infection is leading to consider some anti-rheumatic drugs as potential treatment options for the management of COVID-19. In this review we will critically analyse the evidences on either positive or negative effect of drugs commonly used to treat RA in this particular scenario, in order to optimize the current approach to RA patients.

COVID-19 infection and rheumatoid arthritis: Faraway, so close! / E.G. Favalli, F. Ingegnoli, O. De Lucia, G. Cincinelli, R. Cimaz, R. Caporali. - In: AUTOIMMUNITY REVIEWS. - ISSN 1568-9972. - 19:5(2020), pp. 102523.1-102523.7.

COVID-19 infection and rheumatoid arthritis: Faraway, so close!

E.G. Favalli;F. Ingegnoli;O. De Lucia;G. Cincinelli;R. Cimaz;R. Caporali
2020

Abstract

The outbreak of the new coronavirus infections COVID-19 in December 2019 in China has quickly become a global health emergency. Given the lack of specific anti-viral therapies, the current management of severe acute respiratory syndrome coronaviruses (SARS-CoV-2) is mainly supportive, even though several compounds are now under investigation for the treatment of this life-threatening disease. COVID-19 pandemic is certainly conditioning the treatment strategy of a complex disorder as rheumatoid arthritis (RA), whose infectious risk is increased compared to the general population because of an overall impairment of immune system typical of autoimmune diseases combined with the iatrogenic effect generated by corticosteroids and immunosuppressive drugs. However, the increasing knowledge about the pathophysiology of SARS-CoV-2 infection is leading to consider some anti-rheumatic drugs as potential treatment options for the management of COVID-19. In this review we will critically analyse the evidences on either positive or negative effect of drugs commonly used to treat RA in this particular scenario, in order to optimize the current approach to RA patients.
Rheumatoid arthritis; COVID-19; Treatment; DMARDs; Cytokine release syndrome; Coronavirus
Settore MED/16 - Reumatologia
Settore MED/38 - Pediatria Generale e Specialistica
2020
Article (author)
File in questo prodotto:
File Dimensione Formato  
covid.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 653.88 kB
Formato Adobe PDF
653.88 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/734837
Citazioni
  • ???jsp.display-item.citation.pmc??? 269
  • Scopus 345
  • ???jsp.display-item.citation.isi??? 278
social impact